Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3883-3888

  Yamada, Koichi ^a   Yanagihara, Katsunori ^a   Kaku, Norihito ^a   Harada, Yosuke ^a   Migiyama, Yohei ^a   Nagaoka, Kentaro ^a   Morinaga, Yoshitomo ^a   Nakamura, Shigeki ^a   Imamura, Yoshifumi ^a   Miyazaki, Taiga ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Hasegawa, Hiroo ^a   Mikamo, Hiroshige ^b   Kohno, Shigeru ^a,c  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CYTOKINE; PHOSPHATE BUFFERED SALINE;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM; BODY WEIGHT; BRONCHUS; CONTROL GROUP; CONTROLLED STUDY; HISTOPATHOLOGY; LUNG LAVAGE; MOUSE; MULTIDRUG RESISTANCE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; LUNG; MALE; MICE; MICROBIAL VIABILITY; PNEUMONIA; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; SURVIVAL ANALYSIS;

EID: 84880311469     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00457-13     Document Type: Article

References (30)

1. Young LS, Sabel AL, Price CS. 2006. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multi-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect. Control Hosp. Epidemiol. 28:1247-1254.
2. Munoz-Price LS, Weinstein RA. 2008. Acinetobacter infection. N. Engl. J. Med. 358:1271-1281.
3. Maragakis LL, Perl TM. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46: 1254-1263.
4. Fournier PE, Richet H. 2006. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 42:692-699.
5. Rello J, Ulldemolins M, Lisboa T, Koulenti D, Manez R, Martin-Loeches I, De Waele JJ, Putensen C, Guven M, Deja M, Diaz E. 2011. Determinants of prescription and choice of empirical therapy for hospitalacquired and ventilator-associated pneumonia. Eur. Respir. J. 37:1332-1339.
6. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. 2007. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 45:3352-3359.
7. Reddy T, Chopra T, Macchaim D, Pogue JM, Alangaden G, Salimnia H, Boikov D, Navon-Venezia S, Akins R, Selman P, Dhar S, Kaye KS. 2010. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob. Agents Chemother. 54:2235-2238.
8. Giske CG, Monnet DL, Cars O, Carmeli Y. 2008. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother. 52:813-821.
9. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. 1997. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob. Agents Chemother. 41:345-351.
10. Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibáñez-Martínez J, García-Curiel A, Caballero FJ, Moreno I, Jiménez-Mejías ME. 2000. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Antimicrob. Chemother. 45:493-501.
11. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Ardanuy C, Gudiol F. 2002. Efficacy of colistin versus betalactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 46:1946-1952.
12. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File TM, Jr, Rello J, Menendez R, Marzoratti L, Luna CM, Ramirez JA. 2007. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 175:1086-1093.
13. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A, Markaki V, Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A, Koussoulas V, Kotanidou A, Roussos C, Giamarellou H. 2008. Effect of clarithromycin in patients with sepsis and ventilatorassociated pneumonia. Clin. Infect. Dis. 46:1157-1164.
14. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. 2006. Identification of Acinetobacter baumannii by detection of the blaoxa-51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol. 44:2974-2976.
15. Kaneko Y, Yanagihara K, Kuroki M, Ohi H, Kakeya H, Miyazaki Y, Higashiyama Y, Hirakata Y, Tomono K, Kadota J, Kohno S. 2001. Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilatorassociated pneumonia. Chemotherapy 47:421-429.
16. Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M, Høiby N. 2007. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob. Agents Chemother. 51:3677-3687.
17. Conte JE, Jr, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E. 1996. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40:1617-1622.
18. Yanagihara K, Seki M, Cheng PW. 2001. Lipopolysaccharide induces mucus cell metaplasia in mouse lung. Am. J. Respir. Cell Mol. Biol. 24:66-73.
19. Carry RB, Banerjee SN, Srinivasan A. 2006. Multidrug-resistant Acinetobacter infections, 1995-2004. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., p 27-30. American Society for Microbiology, Washington, D. C.
20. McConnell MJ, Actis L, Pachón J. 2013. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol. Rev. 37:130-155.
21. Yamada K, Yanagihara K, Araki N, Harada Y, Morinaga Y, Akamatsu N, Matsuda J, Izumikawa K, Kakeya H, Yamamoto Y, Hasegawa H, Kohno S, Kamihira S. 2012. Clinical characteristics of tertiary hospital patients from whom Acinetobacter calcoaceticus-Acinetobacter baumannii complex strains were isolated. Intern. Med. 51:51-57.
22. Eveillard M, Soltner C, Kempf M, Saint-André JP, Lemarié C, Randrianarivelo C, Seifert H, Wolff M, Joly-Guillou ML. 2010. The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. J. Infect. 60:154-161.
23. Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. 2010. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J. Infect. Dis. 201:889-897.
24. Byers J, Sole M. 2000. Analysis of factors related to the development of ventilator-associated pneumonia: use of existing databases. Am. J. Crit. Care 9:344-349.
25. Fernández-Cuenca F, Martínez-Martínez L, Pascual A, Perea EJ. 2003. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinetobacter baumannii. Chemotherapy 49:24-26.
26. Wareham DW, Bean DC. 2006. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5:10. doi:10.1186/1476-0711-5-10.
27. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. 2006. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27:224-228.
28. Terao H, Asano K, Kanai K, Kyo Y, Watanabe S, Hisamitsu T, Suzaki H. 2003. Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators Inflamm. 12:195-202.
29. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ. 2010. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir. Res. 11:90. doi:10.1186/1465-9921-11-90.
30. Mortensen BL, Skaar EP. 2012. Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection. Cell. Microbiol. 14: 1336-1344.